4D Pharma PLC
LSE:DDDD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
4D Pharma PLC
LSE:DDDD
|
UK |
|
Tristel PLC
LSE:TSTL
|
UK |
|
Zhejiang Runyang New Material Technology Co Ltd
SZSE:300920
|
CN |
|
Shenzhen Absen Optoelectronic Co Ltd
SZSE:300389
|
CN |
|
Taiga Motors Corp
TSX:TAIG
|
CA |
|
Hangzhou Huning Elevator Parts Co Ltd
SZSE:300669
|
CN |
|
Astra International Tbk PT
OTC:PTAIY
|
ID |
|
G
|
Global Bio-chem Technology Group Co Ltd
HKEX:809
|
HK |
4D Pharma PLC
4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. The firm's LBPs are biologics based on live organisms, namely single strains of bacteria. The company has developed its research to build MicroRx, which is a discovery platform that is able to select those bacteria that have a therapeutic effect in specific diseases. The company uses MicroRx to interrogate its library of bacterial isolates to identify LBPs. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) disease. The company is conducting a phase I/II clinical study of MRx-4DP0004 in patients with poorly controlled asthma.
4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. The firm's LBPs are biologics based on live organisms, namely single strains of bacteria. The company has developed its research to build MicroRx, which is a discovery platform that is able to select those bacteria that have a therapeutic effect in specific diseases. The company uses MicroRx to interrogate its library of bacterial isolates to identify LBPs. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) disease. The company is conducting a phase I/II clinical study of MRx-4DP0004 in patients with poorly controlled asthma.
